A. M. TH. BOERBOOMS, M.D., Ph.D.; M. E. C. JEURISSEN, M.D.; L. B. A. VAN DE PUTTE, M.D., Ph.D.
To the editor: We read with interest the report of Nordstrom and coworkers (1) on radiographic progression in 18 patients with refractory rheumatoid arthritis treated with low-dose methotrexate in a prospective open study. Each patient had three sets of hand, wrist, and foot radiographs: the first set within an average of 33 months before methotrexate therapy, the second at the start of therapy, and the third at an average of 30 months after the start of therapy. Methotrexate may not be a disease-modifying drug because the two rates of radiologic progression before and during therapy were not significantly different.This result
Learn more about subscription options.
Register Now for a free account.
BOERBOOMS AMT, JEURISSEN MEC, VAN DE PUTTE LBA. Pulse Methotrexate Therapy in Rheumatoid Arthritis. Ann Intern Med. 1988;108:905. doi: 10.7326/0003-4819-108-6-905_1
Download citation file:
Published: Ann Intern Med. 1988;108(6):905.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only